Australians living with chronic liver disease will soon have access to a new cheaper medicine on the Pharmaceutical Benefits Scheme (PBS).
Elafibranor (Iqirvo®) will be listed for the first time on the PBS for the treatment of primary biliary cholangitis, a chronic liver disease that damages the bile ducts and causes inflammation and scarring. It can lead to symptoms such as fatigue and itching and may progress to liver failure.
Iqirvo offers a new treatment option for patients with primary biliary cholangitis by reducing inflammation and improving bile flow abnormalities.
In 2024, almost 400 patients accessed a comparable treatment through the PBS. Without PBS subsidy, they may pay more than $71,000 per year of treatment.
PBS listing means eligible patients will pay a maximum of $31.60 per script, or just $7.70 with a concession card. From 1 January 2026, under the government's policy they will pay a maximum of just $25 per script.
Quotes attributable to Minister Butler:
"Affordable access to Iqirvo could be life changing for those living with primary biliary cholangitis, putting this effective but expensive treatment within reach.
"This new treatment option offers hope and better health outcomes for people managing this serious chronic condition.
"The new PBS listing is part of the Albanese Government's commitment to make medicines cheaper and more accessible for all Australians."
